NNovo Nordisk Read More H1 Partners with Novo Nordisk to Scale AI-Driven Clinical Development2026-10-23 H1 Partnership builds on Novo Nordisk’s AI and digital foundation to enhance clinical trial design and execution through…
NNovo Nordisk Read More Lexicon Pharmaceuticals Earns Third $10 Million Milestone Payment from Novo Nordisk Following Achievement of Key Phase 1 Development Milestone for LX98512026-08-24 Lexicon Pharmaceuticals, Inc. LX9851 is a first-in-class, oral non-incretin candidate being developed by Novo Nordisk for the treatment…
NNovo Nordisk Read More Novo Nordisk announces strategic partnership with AWS. Will it be enough to turn around its financial performance?2026-08-10 After kickstarting the GLP-1 wave that transformed the pharma landscape and briefly sending its market value above Denmark’s…
NNovo Nordisk Read More Lexicon (LXRX) Reports $21.1M Q1 Revenue Driven by Novo Nordisk Milestones2026-05-10 Lexicon Pharmaceuticals Inc. (NASDAQ:LXRX) is one of the best fast growing penny stocks to buy right now. On…
NNovo Nordisk Read More Prothena Announces Novo Nordisk Obtains Fast Track Designation from the U.S. FDA for Coramitug (PRX004) in ATTR Amyloidosis with Cardiomyopathy2026-04-29 Coramitug is a potential best-in-class amyloid depleter antibody for the treatment of ATTR amyloidosis with cardiomyopathy1-3 Coramitug is…
NNovo Nordisk Read More Lexicon Pharmaceuticals and Novo Nordisk Announce initiation of Phase 1 study with oral obesity drug candidate LX98512026-03-24 Lexicon Pharmaceuticals, Inc. LX9851 is a first-in-class, oral non-incretin candidate being developed by Novo Nordisk for the treatment…